Filing identity and business context
Important issuer mismatch: The supplied filing is Petra Acquisition, Inc.’s Form 10-Q for the quarter ended September 30, 2020—not a Revelation Biosciences, Inc. filing. Petra is a blank-check company formed to pursue a business combination and had not begun operations by quarter-end. Its IPO closed after the reporting date, on October 13, 2020.
Financial results and position
- Revenue: None reported; Petra expected no operating revenue before completing a business combination.
- Loss: Net loss was $868 for the third quarter and $8,549 for the nine months ended September 30, 2020, primarily general and administrative expenses. No revenue-based margins are meaningful.
- Cash and liquidity: Cash and cash equivalents were $3.321 million at quarter-end, including $3.150 million associated with private warrants; management separately reported approximately $171,000 in its operating bank account and working capital of approximately $13,000.
- Cash flow: Nine-month operating cash use was $8,549; financing activities provided $3.330 million. No investing cash flows were reported.
- Liabilities and equity: Total liabilities were $3.486 million, including $150,000 in related-party advances, a $125,000 related-party note, and a $3.150 million deposit held for private warrants. Stockholders’ equity was $12,813. The related-party note was repaid after quarter-end.
- Debt and obligations: No long-term debt was reported. A $2.8 million deferred underwriting fee is payable only if a business combination is completed; additional contractual and transaction-related fees may apply.
Changes and subsequent events
The filing provides no prior-year comparable income-statement or cash-flow period; Petra was formed in November 2019. Compared with December 31, 2019, quarter-end cash rose from zero to $3.321 million, while total liabilities rose from $26,309 to $3.486 million, largely reflecting financing and private-warrant proceeds.
- After quarter-end, Petra sold 7.0 million IPO units for $70 million gross proceeds and additional units under a partial over-allotment for approximately $2.782 million. It also sold private warrants for $3.150 million and an additional $83,446.
- Following these transactions, approximately $73.509 million was placed in the trust account. The filing reports total IPO transaction costs of $4.541 million, including $2.8 million of deferred underwriting compensation.
- Petra reported that the $125,000 related-party note was repaid after quarter-end. It also reported that quarter-end advances were applied toward the additional private warrants and remaining amounts returned to the Sponsor.
Outlook, risks, and contingencies
Petra intended to use substantially all trust-account proceeds toward a business combination. It had 12 months from the IPO closing to complete one; failure to do so would generally require liquidation and redemption of public shares, while warrants could expire worthless. Management said that, considering the IPO completed after quarter-end, it expected sufficient working capital and borrowing capacity through a business combination or one year from the filing.
- There is no assurance Petra will identify or complete a business combination. Public shareholders may redeem shares in connection with a transaction, and additional equity or debt financing could dilute shareholders or add repayment and covenant risks.
- COVID-19 and market conditions could impede target search, negotiations, financing, or transaction completion; management said the pandemic’s specific financial impact was not readily determinable.
- The filing reported no pending legal proceedings and no off-balance-sheet financing arrangements. Management concluded disclosure controls were effective and reported no material change in internal control during the quarter.
Investor verification points
- Confirm the intended issuer: the supplied document identifies Petra Acquisition, Inc., not Revelation Biosciences, Inc.
- Reconcile the reported $3.321 million quarter-end cash with the approximately $171,000 operating-bank balance and the $3.150 million private-warrant deposit.
- Verify the post-quarter IPO, over-allotment, trust funding, related-party note repayment, and use of advances against the subsequent private-warrant purchase.
- Review the business-combination deadline, redemption terms, deferred underwriting fee, sponsor-related arrangements, and potential dilution from warrants or future financing.